Abstract:Despite biological and technical advances of SBRT and refinement of chemotherapy in the management of pancreatic cancer, disease recurrence is still the predominant cause of death. A significant number of patients may develop local recurrence after treatment, which may greatly debilitate quality of life. These patients may not be amenable for surgery due to its high complication rates. In addition to second-line chemotherapy regimens, re-irradiation with SBRT may be an alternative, which has been used in few studies. However, the techniques were conventional radiotherapy prior to re-irradiation with SBRT and the accumulated doses to organs at risk (OAR) were never reported. Therefore, the goal of the study was to determine the cumulative dose-volume parameters to OAR after two courses of SBRT. All patients received two courses of SBRT for the same region with a partial or complete overlap of two previous dose distributions were enrolled. The maximum dose of OAR was calculated as 50% more than the normal constraint. Due to different doses to target regions and OAR and fractionation schemes, all treatment schedules were recalculated to an Equivalent Dose of 2 Gy per fraction (EQD2). An α/β value of 10 Gy (Gy10) was employed for the tumor dose and acute effects, and the value determined as 3 Gy (Gy3) concerning late effects. Dose distributions, structures sets and CT scans of two treatment plans were extracted from Multiplan® System (version: 4.0.2) and sent to MIM® System (version: 6.6.8) for analysis. Firstly, two CT scans were aligned rigidly via automatic bone matches (translation and rotations). Therefore, for each plan before summation, each of the contoured OARs was registered rigidly. Subsequently, a non-rigid registration was followed in dose summations. After non-rigid registration, the dose distributions of the first plan were projected to the second treatment with both of doses converted to EQD2, which were summed up finally. A total of 24 patients were identified. The median accumulated Dmax, D1 and V10 of the stomach, duodenum and the bowel were 43.87Gy3, 35.28 Gy3 and 107.40cc; 35.53 Gy3, 26.59 Gy3 and 23.98cc; 45.08 Gy3, 36.18 Gy3 and 169.26cc, respectively. The median accumulated Dmax of the spinal cord was 8.42 Gy3. The median cumulative Dmean and D2/3 of the left and right kidney were 5.18 Gy3 and 3.65 Gy3; 3.50 Gy3 and 2.57 Gy3, respectively. The median cumulative Dmean and D50% of the liver was 5.18 Gy3 and 3.64 Gy3, respectively. The median summed dose to the radiation field was 93.38 Gy3. No grade 3-4 toxicity occurred. Partial response and a stable disease to the second irradiation was found in 2 and 12 patients. The cumulative doses to organs at risk as dose constraints were acceptable and safe, which could be used as a reference in the decision for re-irradiation with SBRT after prior SBRT for pancreatic cancer.

A safety study of intraoperative radiation therapy following stereotactic body radiation therapy and multi-agent chemotherapy in the treatment of localized pancreatic adenocarcinoma: study protocol of a phase I trial

Advances Of Stereotactic Body Radiotherapy In Pancreatic Cancer

Adjuvant Therapy with Gemcitabine and Stereotactic Body Radiation Therapy Versus Gemcitabine Alone for Resected Stage II Pancreatic Cancer: A Prospective, Randomized, Open Label, Single-Center Trial.

Neoadjuvant SBRT plus regional nodal irradiation with concurrent capecitabine for patients with resectable pancreatic cancer: Survival analysis of prospective phase 1 trial.

Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS)

Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy

Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas.

Intra-operative radiation for pancreatic cancer: Initial experience at the Hadassah Medical Center.

Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer

Neoadjuvant treatment strategies for resectable pancreas cancer: A propensity-matched analysis of the National Cancer Database

A Phase I Trial of High-Dose SBRT Followed by the Gastrointestinal Shunt Procedure for Local Pancreatic Head and Neck Carcinoma: to Approach a New Mode of Cooperation of Radiation Therapy and Surgery

Dosimetric Benefit Of Adaptive Re-Planning In Pancreatic Cancer Stereotactic Body Radiotherapy

Location, Location, Location: What Should Be Targeted Beyond Gross Disease for Localized Pancreatic Ductal Adenocarcinoma? Proposal of a Standardized Clinical Tumor Volume for Pancreatic Ductal Adenocarcinoma of the Head: the "triangle Volume".

A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer after Modified FOLFIRINOX (NCT01446458).

Postoperative complications following neoadjuvant therapy and surgery in a phase 2 borderline resectable pancreatic cancer clinical trial (Alliance A021501).

A Dosimetric Analysis of Preoperative Intensity-modulated and Image-guided Radiation Therapy with and without Simultaneous Integrated Boost for Locally Advanced Rectal Cancer.

Two Courses Of Stereotactic Body Radiation Therapy For Patients With Pancreatic Cancer: Dose And Toxicity

A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma

Evaluating Dosimetric Constraints for Carbon Ion Radiotherapy in the Treatment of Locally Advanced Pancreatic Cancer

Pancreatic Cancer Adjuvant Radiotherapy Target Volume Design: Based on the Postoperative Local Recurrence Spatial Location